LAG3:FGL1 Assay Service
●
Target
LAG3:FGL1
●
Description
Screening and/or profiling inhibitor compounds against LAG3:FGL1 binding in an ELISA-based biochemical assay.
●
Synonyms
HFREP1, HP-041, LFIRE-1, LFIRE1, fibrinogen like 1; CD223, lymphocyte activating 3
●
Example Data
*Example only, final data may vary.
Assay Details
●
Assay Format
Chemiluminescent
●
Reference Compounds and IC50
Anti-LAG3 Antibody, 0.01 μM
●
Assay Principle
The LAG3:FGL1 Inhibitor Screening Assay is designed to measure the binding of LAG3 (lymphocyte-activation gene 3) to FGL1 (fibrinogen-like protein 1) for screening and profiling applications. The LAG3:FGL1 Inhibitor Screening Assay is performed in a 96-well format using recombinant purified biotinylated FGL1 and recombinant LAG3 (amino acids 23-450), designed as a chemiluminescent ELISA.
Target Details
●
Protein Family
Immunotherapy
●
UniProt
LAG3: P18627; FGL1: Q08830
●
Background
LAG3 (lymphocyte-activation gene 3), also known as CD223, is a cell surface receptor that functions as an inhibitory immune checkpoint. It is found in CD4+ and CD8+ T cells, NK (natural killer) cells, NKT cells and Treg (T regulatory) cells. LAG3 is involved in T cell exhaustion and proliferation. It has several ligands, which include galectin-3, α-synuclein and Fibrinogen-like protein 1 (FGL1). LAG3 and FGL1 are found in tumor cells, where they can serve as immune checkpoints and potentially as oncogenes, and their levels correlate with patient prognosis. LAG3/FGL1 plays a role in immune cell function, cytokine production and tumor growth and metastasis. Several monoclonal antibodies targeting LAG3 are currently being tested, such as relatlimab, and have shown promising results alone or in combination therapy. Blockade of the FGL1-LAG3 interaction can promote antitumor immunity and may benefit patients that have developed tumor immune resistance. For instance, high levels of FGL1 may contribute to gefitinib therapy resistance while high LAG3 levels were found in patients after EGFR (epidermal growth factor receptor)-TKI (tyrosine kinase inhibitor) treatment. A deeper understanding of the importance of this complex in health and disease will allow the development of new cancer therapy strategies.
Delivery
●
Estimated Turnaround
Two to three weeks following delivery of compounds
●
Results
Extensive report with raw and analyzed data, graphs, and detailed protocols. Includes positive control for inhibition.
